Patents Examined by Peter J. Reddig
  • Azide group-containing Fc protein
    Patent number: 11149074
    Abstract: The present invention provides a means capable of efficiently manufacturing a fused substance of an Fc protein and a substance of interest (for example, a peptide). Specifically, the present invention provides an azide group-containing Fc protein represented by formula (1): N3-La-Phe-Lb-Fc??(1) wherein N3 represents an azide group; La represents a bond or a divalent group; Phe represents a residue of phenylalanine or a derivative thereof; Lb represents a lysine residue or an arginine residue, or a peptide linker containing two or more amino acid residues having a lysine residue or an arginine residue at/on the N-terminus; and Fc represents an Fc protein; and the like.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: October 19, 2021
    Assignee: Ajinomoto Co., Inc.
    Inventors: Shigeo Hirasawa, Masumi Taki
  • CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
    Patent number: 11149076
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: October 19, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou
  • Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
    Patent number: 11143656
    Abstract: The present invention relates to a plurality of antigens that together form a panel of immunoreactive molecules suitable for identifying candidates for prostate cancer examination. Methods for identifying antibodies indicative of a pre-malignant or malignant prostate are disclosed. Further disclosed are kits that can be used to practice the above methods.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 12, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Douglas G. McNeel, Brett B. Maricque
  • Chimeric antigen receptors
    Patent number: 11130820
    Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: September 28, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Bitao Liang, Tianjian Li
  • Anti-fibulin-3 antibodies and uses thereof
    Patent number: 11117977
    Abstract: Embodiments described herein provide anti-fibulin-3 antibodies, recombinant proteins that bind specifically to fibulin-3, compositions and the treatment methods comprising these antibodies and recombinant proteins.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: September 14, 2021
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Mariano S. Viapiano, Nandhu Mohan Sobhana, Ennio Antonio Chiocca
  • Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
    Patent number: 11111280
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: September 7, 2021
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Compositions and methods for activation of NK cells killing of prostate cancer and breast cancer cells
    Patent number: 11111303
    Abstract: Certain embodiments are directed to methods of treating LLT1 expressing cancer by administering to a subject having an LLT1 expressing cancer an LLT1 inhibitor.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: September 7, 2021
    Assignee: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER
    Inventors: Purunelloor A. Mathew, Stephen O. Mathew
  • Methods for screening, predicting and monitoring prostate cancer
    Patent number: 11105808
    Abstract: Expression levels of a combination of at least seven genes in a patient sample are measured to separate prostate cancer from normal. Patient samples may be selected from prostate tissue, blood, semen, and urine. A prediction score may be generated based on relative expression levels of the at least seven genes.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: August 31, 2021
    Assignee: HEALTH DISCOVERY CORPORATION
    Inventor: Isabelle Guyon
  • Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
    Patent number: 11098107
    Abstract: The present disclosure relates to antibodies and antibody conjugates having one or more site-specific mutations in the CH2 domain of the heavy chain. The antibody variants disclosed herein can have improved characteristics (e.g., thermal stability, antibody yields, antibody titers, cell-killing) relative to a parent or wild type antibody, including aglycosylated parent or wild type antibodies. Pharmaceutical compositions, diagnostic compositions and kits comprising the same, as well as methods of using these compositions and kits for therapeutic and diagnostic purposes, are also described.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: August 24, 2021
    Assignee: SUTRO BIOPHARMA, INC.
    Inventors: Daniel Calarese, Gang Yin
  • T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptor
    Patent number: 11091532
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 17, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas
  • Antibodies specific for Trop-2 and their uses
    Patent number: 11091544
    Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 17, 2021
    Assignee: Rinat Neuroscience Corp.
    Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
  • Keratin 17 as a prognostic marker for pancreatic cancer
    Patent number: 11092603
    Abstract: The instant application relates to methods for determining pancreatic cancer patient outcome and directing treatment to subjects with pancreatic cancer. The present disclosure further provides methods for measuring expression levels of cytokeratin 17 in a subject having pancreatic cancer, such as pancreatic ductal adenocarcinoma, in order to determine the subject's survival rate and clinical outcome.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: August 17, 2021
    Assignee: The Research Foundation for The State University of New York
    Inventors: Kenneth R. Shroyer, Luisa F. Escobar-Hoyos
  • Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
    Patent number: 11083784
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: August 10, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Anti-PD-1 antibodies
    Patent number: 11072659
    Abstract: Anti-PD-1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: July 27, 2021
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Hsueh Ling Janice Oh, Siok Ping Yeo, Jianrong Lionel Low, Hwee Ching Tan
  • Hybrid immunoglobulin containing non-peptidyl linkage
    Patent number: 11066459
    Abstract: The present invention provides a compound having the structure: A-B - - - Z wherein A is a biologically active structure of the compound; wherein Z is a protein component of the compound, which protein component comprises one or more polypeptides, wherein at least one of the one or more polypeptides comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an Fc domain of an antibody; (ii) bind to an Fc receptor; and (iii) have at their N-terminus a sequence selected from the group consisting of a cysteine or selenocysteine; wherein the dashed line between B and Z represents a peptidyl linkage; and wherein the solid line between A and B represents a nonpeptidyl linkage, as well as intermediates dimers thereof, and processes of producing the compounds of the invention.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: July 20, 2021
    Assignee: BIOMOLECULAR HOLDINGS LLC
    Inventor: Daniel J. Capon
  • Yeast-MUC1 immunotherapeutic compositions and uses thereof
    Patent number: 11065318
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 20, 2021
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
  • Chimeric antigen receptors targeting b-cell maturation antigen
    Patent number: 11066674
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: July 20, 2021
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
    Patent number: 11059902
    Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: July 13, 2021
    Assignee: MORPHOSYS AG
    Inventors: Michael Tesar, Ute Jäger
  • Chimeric antigen receptor molecules and uses thereof
    Patent number: 11059879
    Abstract: Chimeric antigen receptor (CAR) polypeptides are provided comprising an antigen binding domain; a hinge domain; a transmembrane domain and an intracellular signaling domain, wherein the CAR polypeptide binds to a target antigen and wherein the antigen binding domain comprises HCDR sequences from a first antibody that binds to the target antigen and LCDR sequences from a second antibody that binds to the target antigen. In certain aspects, the target antigen is CD123.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: July 13, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Radhika Thokala, Laurence J.N. Cooper, Simon Olivares
  • Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain
    Patent number: 11058722
    Abstract: The present invention provides a chimeric antigen-receptor (CAR)-forming polypeptide comprising: (i) an antigen-binding domain; (ii) a coiled-coil spacer domain; (iii) a transmembrane domain; and (iv) an endodomain. The invention also provides a multimeric CAR formed by association of a plurality of CAR-forming polypeptides by virtue of association of their coiled-coil spacer domains.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: July 13, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba